Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation
Pharmaceuticals · 25.04.2024 · 17 (5) · 553
DOI: 10.3390/ph17050553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.04.2024. Verfasst von Daniel N Marco und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomé…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including CYP3A5*3 and CYP3A4*22 polymorphisms, have an impact on Tac metabolism, dose requirement, and response to Tac. There is limited information regarding this topic in alloHSCT. The CYP3A5 genotype and a low Tac trough concentration/dose ratio (Tac C0/D ratio) can be used to identify fast metabolizers and predict the required Tac dose to achieve target concentrations earlier. We examined 62 Caucasian alloHSCT recipients with a fast metabolizer phenotype (C0/dose ratio ≤ 1.5 ng/mL/mg), assessing CYP3A5 genotypes and acute GVHD incidence. Forty-nine patients (79%) were poor metabolizers (2 copies of the variant *3 allele) and 13 (21%) were CYP3A5 expressers (CYP3A5*1/*1 or CYP3A5*1/*3 genotypes). CYP3A5 expressers had lower C0 at 48 h (3.7 vs. 6.2 ng/mL, p = 0.03) and at 7 days (8.6 vs. 11.4 ng/mL, p = 0.04) after Tac initiation, tended to take longer to reach Tac therapeutic range (11.8 vs. 8.9 days, p = 0.16), and had higher incidence of both global (92.3% vs. 38.8%, p < 0.001) and grade II-IV acute GVHD (61.5% vs. 24.5%, p = 0.008). These results support the adoption of preemptive pharmacogenetic testing to better predict individual Tac initial dose, helping to achieve the therapeutic range and reducing the risk of acute GVHD earlier.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Hematological Diseases, Instituto de Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, S…
- Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, IDIBAPS, CIBERehd, Hospital Clínic, 08036 Barcelona, Spain.
- Department of Immunology, Hospital Clínic, 08036 Barcelona, Spain.
- Department of Pharmacy, Pharmacy Service, Hospital Clínic, 08036 Barcelona, Spain.
ORCID-Profile: Daniel N Marco, Judit Julian, María-Queralt Salas, Inés Monge-Escartín, Gisela Riu-Viladoms, Laura Rosiñol, Francesc Fernández-Avilés, Carmen Martínez
Zitieren
APA
Marco, D. N., Molina, M., Guio, A. M., Julian, J., Fortuna, V., Fabregat-Zaragoza, V. L., Salas, M. Q., Monge-Escartín, I., Riu-Viladoms, G., Carcelero, E., Roma, J. R., Llobet, N., Arcarons, J., Suárez-Lledó, M., Rosiñol, L., Fernández-Avilés, F., Rovira, M., Brunet, M., & Martínez, C. (2024). Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmaceuticals, 17(5), 553. https://doi.org/10.3390/ph17050553
Vancouver
Marco DN, Molina M, Guio AM, Julian J, Fortuna V, Fabregat-Zaragoza VL, et al. Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmaceuticals. 2024;17(5):553. doi:10.3390/ph17050553
BibTeX
@article{Marco2024,
author = {Marco, Daniel N and Molina, Mònica and Guio, Ana-María and Julian, Judit and Fortuna, Virginia and Fabregat-Zaragoza, Virginia-Lucila and Salas, María-Queralt and Monge-Escartín, Inés and Riu-Viladoms, Gisela and Carcelero, Esther and Roma, Joan Ramón and Llobet, Noemí and Arcarons, Jordi and Suárez-Lledó, María and Rosiñol, Laura and Fernández-Avilés, Francesc and Rovira, Montserrat and Brunet, Mercè and Martínez, Carmen},
title = {Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {5},
pages = {553},
doi = {10.3390/ph17050553}
}
EUVIMED